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Abstract 
PYGO2 is member of a conserved family of plant 
homeo domain (PHD)-containing proteins and takes 
part in a wide range of developmental and 
transcriptional processes.  
The most relevant role played by PYGO2 is in Wnt 
signaling pathway, where it is required for β-
catenin/TCF-dependent transcription, even if it has 
showed to have a crucial role also in absence of β-
catenin in tissues such as eye and testis.  
PYGO2 is also known as a chromatin effector 
because of its implication in chromatin remodelling 
processes through regulation of histones 
methylation. 
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Identity 
Other names 
Pygopus Homolog 2 (Drosophila), Pygopus 
Homolog 2, 190004M21 Rik, Pygopus 2 
HGNC (Hugo) PYGO2 
Location 
1q21.3 [link to chromosomal band 1q21. 
[http://atlasgeneticsoncology.org/Bands/1q21.html ] 
Local order 
Starts at 154957026 and ends at 154961782 from 
pter (according to hg38-Dec_2013) 
DNA/RNA 
Note 
The PYGO2 gene (6828 bp) contains a total of 3 
exons and the PYGO2 transcript is 3146 bp. 
Figure 1:  A) Location of PYGO2 gene on chr1. B) Schematic representation of PYGO2 gene, with its three exons. 
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Figure 2:  Schematic representation of PYGO2 gene. 
 
 




Genomic size: 6828 bp. Exons count: 3. This gene 
has 3 transcript (splice variants), 112 orthologues 
and 1 paralogue 
Transcription 
3 transcript variants have been found for this gene 
(font. www.ensembl.org).  
PYGO2-202 ENST00000368457.2 : mRNA 3146 
bp, protein 406 aa  
PYGO2-201 ENST00000368456.1 : mRNA 1306 
bp, protein 369 aa  




PYGO2 protein, composed by 406 aa with a 
molecular mass of 41244 Da, is one of mammalian 
homologs of Drosophila Pygopus, essential for early 
embryonic development, moreover is known to be 
co-activator of the Wnt/β-catenin pathway 
transcriptional complex.  
PYGO2 has two conserved domains, an N-terminal 
homology domain (NHD) and a C-terminal PHD 
zinc finger motif. The NHD domain plays an 
important role in transcriptional activation, taking 
part in the recruitment of histone modification 
factors and being involved in histone methylation 
(Gu et al., 2009). Deletion of NHD domain has been 
associated with 50% reduction of transcriptional 
activity (Liang et al., 2018). Moreover, in the N-
terminal region, there is its nuclear localization 
signal-NLS (from aa 41 to aa 47) and a NPF 
(asparagine-proline-phenylalanine) sequence, which 
takes part in interactions with several proteins 
involved in chromatin remodelling. PYGO2 contains 
a plant homeodomain (PHD) finger, from aa 327 to 
aa 385, composed by 60 aminoacids organized in 
C4HC3 motives, which is important for the PYGO2 
PHD-BCL9-HD1 complex formation (Miller et al., 
2010). 
Expression 
The first molecular cloning and expression analysis 
of a mouse pygopus gene, mpygo2, were described 
by Li et al. (2004). Its transcripts were expressed in 
various adult mouse tissues, such as brain, heart, 
kidney, liver, lung, skin, small intestine, spleen, 
stomach, testis tissue and thymus; at the same 
manner, mpygo2 transcripts were detected in all 
embryos stages examined. The majority of tissues in 
which mpygo2 is expressed requires Wnt signaling 
activation for development, morphogenesis and 
maintenance and this is in line with the involvement 
of this gene in the Wnt signaling. Interestingly, since 
the hair follicle development is a well-known system 
which involves Wnt signaling, mpygo2 expression 
was detected both in developing and adult hair 
follicle (Li et al; 2004). The homologous Drosophila 
pygo gene is necessary to the binding with Lgs 
(legless) and for this reason Drosophila embryos 
homozygous for a pygo mutation, with any Pygo 
activity, die with a severe segment polarity 
phenotype (Kramps et al., 2002); this lethality is not 
found in mice. Mammals have two Pygopus 
homologues, Pygo1 and Pygo2, and the latter seems 
to be dominant (Schwab et al., 2007). The hPygo is 
expressed in a Wnt-dependent manner, in tissues 
such as kidney (Schwab et al., 2007), pancreas 
(Jonckheere et al., 2008), brain (Lake and Kao, 
2003) and mammary gland (Gu et al., 2012); while 
is expressed in a Wnt-independent fashion for eye 
development (Song et al., 2007), spermiogenesis 
(Nair et al., 2008) and embryonic brain patterning 
(Lake and Kao, 2003). hPYGO2 shows high 
expression levels also in several types of cancer, in 
particular in epithelial ovarian cancer cell lines 
(Popadiuk et al., 2006), in several breast malignant 
tumours (Andrews et al., 2007), in gliomas and 
glioblastoma cells (Wang et al., 2010 14; Chen et al., 
2011); recently hPYGO2 has been associated also 
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with adenomas and colon tumours (Brembeck et al., 
2011) and esophageal squamous cell carcinoma 
(Moghbeli et al., 2013). 
Localisation 
PYGO2 is localized in the nucleus (UniProt Pygo2) 
Function 
PYGO2 protein is known to be implicated in 
chromatin remodelling and binding to methylated 
residues on lysine 4 of histone H3 (H3K4me), 
relevant for active transcription (Aasland et al., 
1995). Has also been demonstrated that PYGO2 is 
involved in promoting trimethylation of the same 
residue (H3K4) and acetylation of H3K9/K14 (Gu et 
al., 2009; Chen et al., 2010). In addition, PYGO2 
seems to act as scaffold protein between CTNNB1 
(β-catenin), HNMT, TMPRSS11D (HAT) and the 
chromatin (Chen et al., 2010). This protein is also 
involved in signal transduction through the Wnt 
pathway and it showed a role in nuclear retention of 
β-catenin. Several studies reported that the NHD 
domain of Pygo regulates the transactivation 
activity, instead the PHD domain is responsible for 
the binding, through adaptor proteins, to the N-
terminal domain of β-catenin (Townsley et al., 2004; 
Stadeli and Basler, 2005). Several studies reported 
not only the association with β-catenin to act as co-
activators of the β-catenin/ LEF1/TCF complex 
(Kramps et al., 2002, Stadeli and Basler, 2005), but 
also the β-catenin independent association with 
LEF/TCF target genes (de la Roche and Bienz, 
2007). In two of the most extensively characterized 
PYGO2-requiring tissues, testis and eye, its function 
is β-catenin independent. In the developing kidney 
PYGO2 shows wide expression in the ureteric bud 
and PYGO2 mutant phenotype resulted in reduced 
branching morphogenesis of this (Schwab et al., 
2007). Similarly, a mutant phenotype has been 
observed also in pancreas, where lack of PYGO2 
results in pancreas hypoplasia and defective 
endocrine cell differentiation (Jonckheere et al., 
2008). PYGO2 demonstrated to play a role in 
development also in lung morphogenesis, because 
mpygo2-/- showed lungs pale and smaller than the 
wild type and with airways defects (Boan et al., 
2007). Concerning the tissues where PYGO2 is not 
linked to the Wnt signalling, it showed to play a role 
in lens development, because of its expression in 
tissues of early eye such as optic vesicle and 
presumptive lens (Song et al., 2007), and during 
spermatogenesis, as a matter of fact its block leads to 
spermiogenesis arrest and infertility (Nair et al., 
2008). 
Homology 
PYGO2 is conserved in human, mouse, rat, 
chimpanzee, cattle, dog and chicken. 
Mutations 
Somatic 
Some somatic mutations have been identified and 
described by COSMIC (Catalogue of Somatic 
Mutation In Cancer) and they are listed mostly as 
substitutions and frameshift insertion or deletions; 
their role in disease has not yet been clarified. 
 
Figure 4:  Overview of the major types of mutations 
occurring in PYGO2. 
Implicated in 
Metastatic prostate cancer 
Prostate cancer (PrCa) is the most common 
malignancy in men. Since PYGO2 mRNA and 
protein show elevated levels in many androgen-
dependent and androgen-independent PrCa cell lines 
(Kao et al., 2018), there could be evidences of his 
involvement in tumor progression. PYGO2 
overexpression promotes prostate tumor growth and 
moreover regional lymph nodes invasion; instead its 
depletion results in cell cycle arrest, decreasing of 
cell proliferation and reduction of cell invasion (Lu 
et al., 2018). 
Glioma 
Glioma is one of the most common type of tumor 
that occurs in brain and spinal cord. Zhou et al (2016) 
found PYGO2 mRNA expression in the majority of 
primary glioma tissue of patients and this was 
increased compared to control. Interestingly, this 
overexpression correlates with some clinic-
pathological features, such as the age and the tumor 
grade: it is present in patients over 50 years and in 
advanced tumors. Knockdown of PYGO2, in human 
brain glioma cell lines, leads to decreased mRNA 
and protein levels of some Wnt/β-catenin pathway 
downstream targets, acting through regulation of 
H2K4me3 level on their promoters. 
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Hepatic carcinoma 
Hepatic carcinoma (HCC) is a primary malignancy 
of the liver. There are evidences (Zhang et al., 2015) 
that in HCC tissues PYGO2 mRNA and protein are 
highly expressed and it could play a role in HCC 
development and progression, showing positive 
regulation on cell migration. This positive regulation 
could be explained considering the fact that PYGO2 
can bind to the promoter of CDH1 (E-cadherin) 
regulating its expression. Zhang and colleagues 
demonstrated that down-modulation of PYGO2 
increased E-cadherin expression, resulting in 
increased cellular adhesion; indeed, a weak presence 
of PYGO2, and a subsequently wider presence of E-
cadherin, leads to decreased invasion capability and 
metastasis formation. 
Colon cancer 
Colon cancer affects the large intestine and the 
primary source for the development of this type of 
cancer is the deregulation of Wnt/β-catenin signaling 
pathway, resulting in an overactivation of the entire 
pathway. Brembeck and colleagues (2011) 
demonstrated a PYGO2 overexpression in human 
colon cancer and for this reason has been 
investigated his oncogenic role. There are evidences 
that PYGO2 deletion decelerates tumor formation in 
chemically induced colon cancer, decreasing in a 
significant manner tumor number and size. This 
delay is caused by inhibition of Wnt signaling, 
because of the capability of PYGO2 to reduce 
overexpression of some Wnt/β-catenin target genes 
(Talla and Brembeck, 2016). 
Non-small cell lung carcinoma 
Non-small cell lung carcinoma (NSCLC) represents 
about 80% to 85% of lung cancers. Liu et al. (2013) 
demonstrated PYGO2 nuclear accumulation in more 
than half of the lung cancer samples analysed and 
determined a correlation between PYGO2 
expression and some NSCLC clinic-pathological 
features, such as stages of tumor and survival. 
Moreover, viability assays demonstrated that 
PYGO2 silencing results in inhibition of lung cancer 
cells proliferation, via regulation of cell cycle and 
apoptosis. 
Esophageal squamous cell 
carcinoma 
Esophageal squamous cell carcinoma (ESCC) is a 
type of esophageal carcinoma that usually affects the 
upper or middle third part. For the first time 
Moghbeli et al. reported an association between the 
overexpression of PYGO2 and clinic-pathological 
features of ESCC, such as the grade of tumor 
differentiation, the tumor size and the age of patients. 
The exact role of PYGO2 in ESCC is unclear, but it 
has been demonstrated to have a significant 
correlation with EGFR, a type I transmembrane 
receptor which is broadly involved in various 
squamous cell carcinomas. Apparently, PYGO2 
could act as transcriptional activator of EGFR, 
promoting the ESCC tumorigenesis 
Epithelial ovarian cancer 
Epithelial ovarian cancer is the most common type 
of ovarian cancer, almost 90% of ovarian cancers are 
epithelial. PYGO2 shows overexpression in six 
malignant epithelial ovarian cancer cell lines, 
compared to control. Interestingly it is 
overexpressed in both ovarian cancer tumors 
endometrioid and non-endometrioid, that differ from 
each other, respectively, for the activation and 
inactivation of Wnt pathway. Popadiuk et al. 
demonstrated that knockdown of Pygo2 results in 
reduction of mRNA and protein levels and it causes 
growth's inhibition. 
Breast cancer 
Breast cancer is the leading malignant female 
disease with a high percentage of chemoresistance. 
Watanabe et al. (2014) demonstrated that PYGO2 
plays an important role in mammary tumorigenesis 
and its loss leads to delays in mammary tumors 
formation in mice, acting via both Wnt-dependent 
and independent mechanism. PYGO2 seems to play 
a role also in the onset of chemoresistance, activating 
a drug efflux transporter, ABCB1 (MDR1). To 
confirm this hypothesis, Zhang et al. (2016) 
demonstrated that knockdown of PYGO2 results in 
restoring sensitivity for chemotherapeutic drug. 
Idiopathic azoospermia 
Idiopathic azoospermia is a medical condition which 
implies the absence of sperm in semen. Two non-
synonymous SNP mutations in PYGO2 have been 
reported to be implicated in this disease: 
rs61758740, M141I, has no effect on protein 
structure, and rs141722381, N240I, disrupts the 
protein structure and so it can be disease causing (Ge 
et al., 2015). These SNPs are reported in the National 
Center for Biotechnology Information SNP database 
(NCBI SNPdb). 
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